Search Result

Results for "

hypertrophied hearts

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (3) Akt (6) AMPK (1) Angiotensin Receptor (2) Angiotensin-converting Enzyme (ACE) (5) Anion Exchangers (1) Apoptosis (6) Calcium Channel (1) Carbonic Anhydrase (1) Cytochrome P450 (1) Dopamine β-hydroxylase (2) Drug Derivative (3) Drug Isomer (1) Endothelin Receptor (5) ERK (1) Exosomes (1) Ferroptosis (1) G Protein-coupled Receptor Kinase (GRK) (3) GSK-3 (2) HDAC (1) Histamine Receptor (2) HSP (1) iGluR (1) JAK (1) Monocarboxylate Transporter (1) mTOR (3) Neprilysin (1) NF-κB (2) NO Synthase (1) Nucleoside Antimetabolite/Analog (1) Ornithine decarboxylase (ODC) (1) P2X Receptor (1) p38 MAPK (1) PAI-1 (1) PI3K (4) PKC (1) PKD (1) Reference Standards (4) RXFP Receptor (1) Sirtuin (1) STAT (3) TGF-beta/Smad (4) TNF Receptor (1) TRP Channel (1) VEGFR (1)
By Research Areas:	Cancer (9) Cardiovascular Disease (31) Endocrinology (2) Inflammation/Immunology (5) Metabolic Disease (4) Neurological Disease (6)

By Targets:

Adrenergic Receptor (3)

Akt (6)

AMPK (1)

Angiotensin Receptor (2)

Angiotensin-converting Enzyme (ACE) (5)

Anion Exchangers (1)

Apoptosis (6)

Calcium Channel (1)

Carbonic Anhydrase (1)

Cytochrome P450 (1)

Dopamine β-hydroxylase (2)

Drug Derivative (3)

Drug Isomer (1)

Endothelin Receptor (5)

ERK (1)

Exosomes (1)

Ferroptosis (1)

G Protein-coupled Receptor Kinase (GRK) (3)

GSK-3 (2)

HDAC (1)

Histamine Receptor (2)

HSP (1)

iGluR (1)

JAK (1)

Monocarboxylate Transporter (1)

mTOR (3)

Neprilysin (1)

NF-κB (2)

NO Synthase (1)

Nucleoside Antimetabolite/Analog (1)

Ornithine decarboxylase (ODC) (1)

P2X Receptor (1)

p38 MAPK (1)

PAI-1 (1)

PI3K (4)

PKC (1)

PKD (1)

Reference Standards (4)

RXFP Receptor (1)

Sirtuin (1)

STAT (3)

TGF-beta/Smad (4)

TNF Receptor (1)

TRP Channel (1)

VEGFR (1)

By Research Areas:

Cancer (9)

Cardiovascular Disease (31)

Endocrinology (2)

Inflammation/Immunology (5)

Metabolic Disease (4)

Neurological Disease (6)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139665

VB124 Maximum Cited Publications 7 Publications Verification	Monocarboxylate Transporter	Cardiovascular Disease
VB124 is an orally active, potent, and selective MCT4 inhibitor. VB124 can specifically inhibit lactate efflux with IC₅₀s of 8.6 nM and 19 nM for lactate import and export in MDA-MB-231 cells, respectively. VB124 is highly selective for MCT4 over MCT1. VB124 can be used for the research of cardiac hypertrophy, heart failure, and metabolism .

HY-158426

2-APQC 1 Publications Verification	Sirtuin	Cardiovascular Disease
2-APQC is an orally active and selective agonist of Sirtuin-3 (SIRT3) (K_d=2.756 μM), antagonizes Isoproterenol/ISO (HY-B0468)-induced cytotoxicity. 2-APQC activates the SIRT3-PYCR1 axis to enhance mitochondrial proline metabolism and inhibit the ROS-p38MAPK pathway by inhibiting signaling pathways such as mTOR-p70S6K, JNK, and TGF-β/Smad3. 2-APQC also activates the AMPK-Parkin axis to alleviate myocardial hypertrophy and fibrosis and protect cardiac function. 2-APQC can be used in the study of heart failure .

HY-B0592

Trandolapril RU44570	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-P1237

C-Type Natriuretic Peptide (CNP) (1-22), human 2 Publications Verification	Histamine Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
C-Type Natriuretic Peptide (CNP) (1-22), human, a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor .

HY-128483

Fusaric acid	TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor	Cardiovascular Disease Endocrinology Cancer
Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β₁/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .

HY-143248

KR-39038 1 Publications Verification	G Protein-coupled Receptor Kinase (GRK) HDAC	Cardiovascular Disease
KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC₅₀ of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research .

HY-168894

CT-1	Ferroptosis JAK STAT p38 MAPK AMPK GSK-3 Apoptosis HSP TNF Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease Cancer
CT-1 is a secreted protein belonging to the IL-6 cytokine family. Overexpression of CT-1 enhances cell proliferation, migration and angiogenesis via the ADMA/DDAH pathway. CT-1 inhibits the growth of triple-negative breast cancer cells by simultaneously inducing Ferroptosis in N2-type tumor-associated neutrophils and cancer cells. CT-1 activates the Jak/STAT-3, p42/p44 MAPK and AMPK pathways, and inhibits GSK-3β activity through phosphorylation to induce cardiomyocyte hypertrophy. CT-1 enhances the viability of cardiomyocytes and neurons, reduces cell Apoptosis, induces the expression of heat shock proteins (HSP) and BNP, and inhibits TNF levels. CT-1 exerts anti-tumor activity in mouse models of triple-negative breast cancer. CT-1 improves cognitive impairment in mice. CT-1 is applicable to the research of ischemic heart disease, triple-negative breast cancer, myocardial hypertrophy, Parkinson's disease, hypertensive heart disease, myocardial infarction, acute Chagas cardiomyopathy, high-fat diet-induced cognitive impairment and diabetes-related cognitive impairment .

HY-W042301

Xipamide	Anion Exchangers Carbonic Anhydrase Endothelin Receptor	Cardiovascular Disease
Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na ⁺/Cl ^--potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl ^-/NaCO₃ ^- anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca ²⁺ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites .

HY-N2000

Bellidifolin 1 Publications Verification	STAT PI3K mTOR Akt	Neurological Disease Inflammation/Immunology Cancer
Bellidifolin is an orally active compound with antiproliferative, anti-inflammatory and antioxidant properties. Bellidifolin modulates key signaling pathways including STAT3, PI3K-Akt, mTOR and BRD4, and inhibits the viral protein R (Vpr). Bellidifolin induces cell cycle arrest and apoptosis, exerts significant antifibrotic effects, and protects the heart, liver and nervous system. Bellidifolin is applicable to the research of various diseases such as lung cancer, non-alcoholic fatty liver disease, myocardial hypertrophy and ischemic cranial nerve injury .

HY-P1237A

C-Type Natriuretic Peptide (CNP) (1-22), human TFA 2 Publications Verification	Histamine Receptor Endothelin Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor .

HY-P10641

Heart-homing peptide	Exosomes STAT ERK Akt	Cardiovascular Disease
Heart-homing peptide is a heart-targeting peptide with the sequence CRPPR that mediates cardiac endothelial targeting and accumulates in cardiac tissues. Heart-homing peptide mediates the translocation of liposomal and exosomal cargos across cardiac endothelium into interstitial tissues, enhances the accumulation of exosomes in the heart, and inhibits the GP130-STAT3/ERK1/2/AKT pathway. Heart-homing peptide accumulates at sites of ischemia/reperfusion, myocardial infarction and hypertrophy in mice. Heart-homing peptide can be used for the research of cardiovascular diseases .

HY-W414915

Valsartan methyl ester CGP 48933 methyl ester	Drug Derivative Angiotensin Receptor	Cardiovascular Disease Cancer
Valsartan (CGP 48933) methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective and orally active angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .

HY-N6065

Praeruptorin A 3 Publications Verification (+)-Praeruptorin A	Calcium Channel Drug Isomer Cytochrome P450 iGluR Apoptosis	Cardiovascular Disease Neurological Disease
Praeruptorin A ((+)-Praeruptorin A) is an orally active isomer of (±)-Praeruptorin A (HY-N0081). Praeruptorin A also acts as a Calcium channel blocker. Praeruptorin A can be isolated from Peucedanum. Praeruptorin A serves as a substrate for CYP3A4. Praeruptorin A downregulates NMDA receptors containing GluN2B and inhibits neuronal Apoptosis. Praeruptorin A mediates vasodilation, inhibits vascular hypertrophy and reduces blood pressure. Praeruptorin A can be used in research related to neurological diseases, myocardial ischemia, heart failure, exertional angina, renovascular hypertension and spontaneous hypertension .

HY-132187

Sphingosylphosphorylcholine	TGF-beta/Smad TRP Channel Apoptosis PAI-1	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Sphingosylphosphorylcholine is a bioactive lipid and a major component of plasma high-density lipoprotein that binds to OGR1 with a K_d of 33.3 nM. Sphingosylphosphorylcholine triggers delayed phosphorylation of Smad2, upregulates α-SMA expression, and activates TRPM3. Sphingosylphosphorylcholine reduces Apoptosis and upregulates the expression of uPA and its receptor uPA-R. Sphingosylphosphorylcholine exerts anti-apoptotic, anti-cardiac hypertrophy and pro-wound healing effects. Sphingosylphosphorylcholine induces scratching behavior in mice. Sphingosylphosphorylcholine is used in studies related to atopic dermatitis, promyelocytic leukemia, heart failure, myocardial ischemia/reperfusion injury, ovarian cancer, breast cancer, pancreatic cancer, and skin wound healing disorders in genetically impaired healing diabetes .

HY-128142

PKC/PKD-IN-1	PKD PKC	Cardiovascular Disease
PKC/PKD-IN-1 (Compound 13C) is an orally active dual protein kinase C/D (PKC/PKD) inhibitor with an IC₅₀ value of 0.6 nM for PKD1. PKC/PKD-IN-1 can attenuate high-salt diet-induced cardiac hypertrophy and can be used in the study of heart failure .

HY-160706

HHQ16	Drug Derivative	Cardiovascular Disease
HHQ16 is an orally active derivative of Astragaloside IV (HY-N0431). HHQ16 effectively reverses infarction-induced hypertrophy and heart failure by targeted degrading lnc4012/lnc9456 and antagonizing their effects on G3BP2/NF-κB signaling .

HY-114683

KS370G	TGF-beta/Smad	Cardiovascular Disease
KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy .

HY-106994A

Nebentan potassium YM598	Endothelin Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ET_A receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [ ¹²⁵I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with K_i of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .

HY-P11297

AC-SDKP-NH2	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
AC-SDKP-NH2 is a substrate peptide of Angiotensin converting enzyme (ACE). AC-SDKP-NH2 has anti-inflammatory and anti-fibrotic activities. AC-SDKP-NH2 directly acts on tissues and prevents or reverses them from excessive fibrosis, but fails to reduce blood pressure and left ventricular hypertrophy (LVH). AC-SDKP-NH2 attenuates inflammation and cell differentiation, proliferation and migration, therefore reducing fibrosis in the heart, vessels and kidneys in mice model. AC-SDKP-NH2 can be used for cardiovascular diseases such as hypertension research .

HY-114941

Aladotril BP1137	Angiotensin-converting Enzyme (ACE) Neprilysin	Cardiovascular Disease
Aladotril (BP1137) is the inhibitor for neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), that ameliorates the cardiac hypertrophy in rats, without decreasing the blood pressure. Aladotril can be used in research about heart failure and cardiac remodeling after myocardial infarction .

HY-173005

JZ19	PI3K Akt GSK-3 Apoptosis	Cardiovascular Disease
JZ19 reduces the LDH and ROS levels, and exhibits antioxidant activity against oxygen-glucose deprivation (OGD)-induced cardiomyocyte injury. JZ19 reverses Isoproterenol (HY-B0468)-induced cardiomyocyte hypertrophy and apoptosis through PI3K-AKT-GSK3β signaling pathway. JZ19 alleviates Isoproterenol (HY-B0468)-induced heart failure in mouse models .

HY-W414915R

Valsartan methyl ester (Standard) CGP 48933 methyl ester (Standard)	Reference Standards Drug Derivative Angiotensin Receptor	Cardiovascular Disease
Valsartan (CGP 48933) methyl ester (Standard) is the analytical standard of Valsartan methyl ester (HY-W414915). This product is intended for research and analytical applications. Valsartan methyl ester is the methyl ester derivative of Valsartan (HY-18204). Valsartan is a selective angiotensin II type 1 (AT1) receptor blocker (ARB) with potent antihypertensive and cardioprotective effects. Valsartan competitively binds to AT1 receptors, inhibiting the binding of angiotensin II to AT1 receptors, thereby blocking angiotensin II-mediated vasoconstriction, sodium retention, and myocardial hypertrophy signaling pathways. Valsartan reduces systolic blood pressure in L-NAME-induced hypertensive rats. Valsartan can be used for the study and treatment of arterial hypertension, hypertensive heart disease, and heart failure .

HY-128483R

Fusaric acid (Standard)	TGF-beta/Smad PI3K NF-κB Akt Apoptosis Dopamine β-hydroxylase mTOR Adrenergic Receptor Reference Standards	Cardiovascular Disease Endocrinology Cancer
Fusaric acid (Standard) is the analytical standard of Fusaric acid (HY-128483). This product is intended for research and analytical applications. Fusaric acid is an orally active multi-pathway inhibitor with the activity of inducing oxidative stress and apoptosis. Fusaric acid can chelate divalent metal cations, damage mitochondrial membrane structure, and activate apoptosis-related proteases such as Caspase-3/7, -8, and -9. Fusaric acid also regulates Bax/Bcl-2 protein, inhibits fibrosis-related signaling pathways such as NF-κB, TGF-β₁/SMADs, and PI3K/AKT/mTOR, and reduces collagen deposition. Fusaric acid is also a dopamine β-hydroxylase inhibitor, which reduces endogenous levels of norepinephrine and epinephrine in the brain, heart, spleen, and adrenal glands. Fusaric acid can play a role in myocardial fibrosis and improve cardiac hypertrophy in heart disease, and can also be used in the study of esophageal cancer and liver cancer .

HY-106994

Nebentan YM598 free base	Endothelin Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Nebentan (YM598 free base) is a potent, selective and orally active non-peptide endothelin ET_A receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan inhibits [ ¹²⁵I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with K_i of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .

HY-B0592R

Trandolapril (Standard) RU44570 (Standard)	Reference Standards Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (Standard) is the analytical standard of Trandolapril. This product is intended for research and analytical applications. Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-B0592A

Trandolapril hydrochloride RU44570 hydrochloride	Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Trandolapril (RU44570) hydrochloride is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolapril hydrochlorideat. Trandolapril hydrochloride is an orally active angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) .

HY-120168

CCG 258001	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
CCG 258001 is a GRK inhibitor with IC₅₀ values of 0.29, 51.8, and 33 µM against GRK2, GRK1, and GRK5, respectively. CCG 258001 inhibits GRK activity in cardiomyocytes and other muscle cells. CCG 258001 is applicable to the research of heart diseases, including heart failure, myocardial hypertrophy, and hypertension .

HY-120718

CCG 224061	G Protein-coupled Receptor Kinase (GRK)	Cardiovascular Disease
CCG 224061 is a G protein-coupled receptor kinase 2 (GRK2) inhibitor with a IC₅₀ of 0.066 μM. CCG 224061 inhibits GRK activity in cardiomyocytes . CCG 224061 is applicable to research related to heart disease, heart failure, myocardial hypertrophy and hypertension .

HY-107155

β-Blocker B-24/76	Adrenergic Receptor Ornithine decarboxylase (ODC)	Cardiovascular Disease
β-Blocker B-24/76 is a beta adrenoceptor blocker. β-Blocker B-24/76 exhibits beta 1-adrenoceptor blocking and beta 2-adrenoceptor stimulating properties. β-Blocker B-24/76 can suppress the increased ornithine decarboxylase activity in hypertrophied hearts. β-Blocker B-24/76 can be used for the research of cardiovascular disease .

HY-P992108

Efadirelaxin alfa RELAX10	RXFP Receptor Akt NO Synthase VEGFR	Cardiovascular Disease
Efadirelaxin alfa (RELAX10) is a highly selective agonist of relaxin/insulin-like family peptide receptor RXFP1. After subcutaneous administration in animal experiments, Efadirelaxin alfa exhibits a significantly prolonged terminal half-life (7 days in mice, 3.75 days in rats), and shows no activity against related receptors such as RXFP2 and RXFP3. Efadirelaxin alfa has significant anti-cardiac hypertrophy and anti-fibrotic effects. Efadirelaxin alfa effectively attenuates and reverses cardiac hypertrophy and collagen deposition by regulating the TGF-β1/Smad2 and AKT/eNOS signaling pathways. Efadirelaxin alfa improves cardiac systolic function without causing fluctuations in blood pressure or heart rate, demonstrating favorable safety. Efadirelaxin alfa is currently mainly used in studies related to heart failure .

HY-106994AR

Nebentan potassium (Standard) YM598 (Standard)	Reference Standards Endothelin Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Nebentan potassium (Standard) (GT-2331 maleate (Standard)) is the analytical standard of Nebentan (potassium) (HY-106994A). This product is intended for research and analytical applications. Nebentan potassium (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan (HY-A0013). Nebentan potassium inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with K_i of 0.697 nM and 569 nM, respectively . YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo .

HY-182642

MRS2339	P2X Receptor Nucleoside Antimetabolite/Analog	Cardiovascular Disease
MRS2339 is a ribose-modified nucleotide and a nucleotidase-resistant P2 receptor agonist. MRS2339 activates P2X4R. MRS2339 induces ionic currents via P2X receptors, reduces cardiomyocyte cross-sectional area and heart weight/body weight ratio, lacks vasodilatory activity, and extends the lifespan of mice with cardiomyopathy. MRS2339 can be used in research related to heart failure and cardiomyopathy .

Cat. No.	Product Name	Target	Research Area